SKBI [SKYSTAR BIO-PHARMACEUTICAL] SC 13G/A: (Original Filing)

[SCHEDULE 13G 3 (Amendment No.ystar Bio-Pharmaceuticalmpany (Name of Issuer)mmon Stock 830884102 May05,2009 o x o * The remainder of thisver page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendmentntaining information which wouldter the disclosures provided in a]

By | 2016-02-05T04:31:49+00:00 March 8th, 2010|Categories: Chinese Stocks, SEC Original, SKBI|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL] SC 13G/A: SCHEDULE 13G 3 (Amendment No.ystar Bio-Pharmaceuticalmpany (Name of

[SCHEDULE 13G 3 (Amendment No.ystar Bio-Pharmaceuticalmpany (Name of Issuer)mmon Stock 830884102 May05,2009 o x o * The remainder of thisver page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendmentntaining information which wouldter the disclosures provided in a]

By | 2016-02-05T04:32:39+00:00 March 8th, 2010|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] 10-K: (Original Filing)

[Form 10-K (Mark one) x For the fiscal year ended: December 31, 2009 o For the transition period from ______________ to _____________ China Pharma Holdings, Inc. Delaware 73-1564807 (State or other jurisdiction (I.R.S. Employer I.D. No.) incorporation or organization) 2nd Floor, No. 17, Jinpan Road, Haikou, Hainan Province, China 570216 0086-898-66811730 (China) None Securities registered under Section 12(b) of the] [Anhui Fuyang Xinte Pharmaceutical Company , S ales Contract Name of Product Quality standard and specification Unit Unit price Quantity Amount(RMB) Tiopronin kg 1200.00 1000 1200000 Hepatocyte growth—promoting factor kg 9000.00 40 3600000 Micro-fiber products 33.00 8000 264000 Medicinal Starch 4.6 5000 23000 Pre-gel starch 8.5 4000 34000 Total amount Five million one hundred and twenty one thousand only 5,121,000.00] [Raw Material Purchase / Sales Contract Date signed : 2009-03-25 Place: Haikou Accordingly to friendly negotiation, both Parties agree to the term and condition stated as following, 1 Name, specification, quantity and total amount of product Name of Product Quality standard and specification Unit Unit price Quantity Amount(RMB) Brain tissue initial liquid ml 2.00 873,950 1,747,900.00 FDHB mg 400.00 7,300] [Sale s Contract of Helpson Medical & Biotechnology Co., Ltd. C ontract No. Signed at: Arrival port: C ustom No.: B usiness No.: According to the related stipulation of "People's Republic of China Law of contract", after consulting unanimously, both sides sign this contract: NO. Name of Commodity ,Specifications Unit Quantity Unit Price(RMB ) Total Amount Time of Shipment Buflomedil] [Sale s Contract of Helpson Medical & Biotechnology Co., Ltd. C ontract No. Signed at: Arrival port: C ustom No. : B usiness No. : According to the related stipulation of "People's Republic of China Law of contract", after consulting unanimously, both sides sign this contract: NO. Name of Commodity, Specifications Unit Quantity Unit Price(RMB ) Total Amount Time of] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with] [CERTIFICATION OF CHIEF FINANC IAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Frank Waung, certify that: Frank Waung Chief Financial Officer EX-31.2 7 cph10kex312123109.htm] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER 18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Zhilin Li Chief Executive Officer EX-32.1 8 cph10kex321123109.htm] [CERTIFICATION OF CHIEF FINANCIAL OFFICER 18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Frank Waung Chief Financial Officer EX-32.2 9 cph10kex322123109.htm]

By | 2016-03-03T20:51:20+00:00 March 4th, 2010|Categories: Chinese Stocks, CPHI, SEC Original|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] 10-K: Form 10-K (Mark one) x For the fiscal

[Form 10-K (Mark one) x For the fiscal year ended: December 31, 2009 o For the transition period from ______________ to _____________ China Pharma Holdings, Inc. Delaware 73-1564807 (State or other jurisdiction (I.R.S. Employer I.D. No.) incorporation or organization) 2nd Floor, No. 17, Jinpan Road, Haikou, Hainan Province, China 570216 0086-898-66811730 (China) None Securities registered under Section 12(b) of the] [Anhui Fuyang Xinte Pharmaceutical Company , S ales Contract Name of Product Quality standard and specification Unit Unit price Quantity Amount(RMB) Tiopronin kg 1200.00 1000 1200000 Hepatocyte growth—promoting factor kg 9000.00 40 3600000 Micro-fiber products 33.00 8000 264000 Medicinal Starch 4.6 5000 23000 Pre-gel starch 8.5 4000 34000 Total amount Five million one hundred and twenty one thousand only 5,121,000.00] [Raw Material Purchase / Sales Contract Date signed : 2009-03-25 Place: Haikou Accordingly to friendly negotiation, both Parties agree to the term and condition stated as following, 1 Name, specification, quantity and total amount of product Name of Product Quality standard and specification Unit Unit price Quantity Amount(RMB) Brain tissue initial liquid ml 2.00 873,950 1,747,900.00 FDHB mg 400.00 7,300] [Sale s Contract of Helpson Medical & Biotechnology Co., Ltd. C ontract No. Signed at: Arrival port: C ustom No.: B usiness No.: According to the related stipulation of "People's Republic of China Law of contract", after consulting unanimously, both sides sign this contract: NO. Name of Commodity ,Specifications Unit Quantity Unit Price(RMB ) Total Amount Time of Shipment Buflomedil] [Sale s Contract of Helpson Medical & Biotechnology Co., Ltd. C ontract No. Signed at: Arrival port: C ustom No. : B usiness No. : According to the related stipulation of "People's Republic of China Law of contract", after consulting unanimously, both sides sign this contract: NO. Name of Commodity, Specifications Unit Quantity Unit Price(RMB ) Total Amount Time of] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with] [CERTIFICATION OF CHIEF FINANC IAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Frank Waung, certify that: Frank Waung Chief Financial Officer EX-31.2 7 cph10kex312123109.htm] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER 18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Zhilin Li Chief Executive Officer EX-32.1 8 cph10kex321123109.htm] [CERTIFICATION OF CHIEF FINANCIAL OFFICER 18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Frank Waung Chief Financial Officer EX-32.2 9 cph10kex322123109.htm]

By | 2016-03-03T20:52:21+00:00 March 4th, 2010|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] 10-K: (Original Filing)

[Form 10-K (Mark one) x For the fiscal year ended: December 31, 2009 o For the transition period from ______________ to _____________ China Pharmas, Delaware 73-1564807 (State or other jurisdiction (I.R.S. Employer I.D. No.)orporation or organization) 2nd Floor, No. 17, Jinpan Road, Haikou, Hainan Province, China 570216 0086-898-66811730 (China)] [Anhui Fuyang Xinte Pharmaceuticalmpany , Sesntract Name of Product Quality standard andecification Unit Unit price Quantity Amount(RMB) Tiopronin 1200.00 1000 1200000 Hepatocyte growthpromoting factor 9000.00 40 3600000 Micro-fiber products 33.00 8000 264000 Medicinal Starch 4.6 5000 23000 Pre-gel starch 8.5 4000 34000 Total amount Five million one hundred and twenty one thousand only] [Raw Material Purchase /lesntractte signed : 2009-03-25 Place: Haikou Accordingly to friendly negotiation, both Partiesree to the term andndition stated following, 1 Name,ecification, quantity and total amount of product Name of Product Quality standard andecification Unit Unit price Quantity Amount(RMB) Brain tissue initial liquid] [Sale sntract of Helpson Medical & Biotechnology C ontract No. Signed at: Arrival port: C ustom No.: B usiness No.: According to the related stipulation of "People's Republic of China Law ofntract", afternsulting unanimously, both sides sign thisntract: NO. Name ofmmodity ,Specifications Unit Quantity] [Sale sntract of Helpson Medical & Biotechnology C ontract No. Signed at: Arrival port: C ustom No. : B usiness No. : According to the related stipulation of "People's Republic of China Law ofntract", afternsulting unanimously, both sides sign thisntract: NO. Name ofmmodity,ecifications] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER OF THERBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 2)Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not] [CERTIFICATION OF CHIEF FINANC IAL OFFICER OF THERBANES-OXLEY ACT OF 2002 I, Frank Waung, certify that: Frank Waung Chief Financial Officer cph10kex312123109.htm 7 EX-31.2] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER 18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 Zhilin Li Chief Executive Officer cph10kex321123109.htm 8 EX-32.1] [CERTIFICATION OF CHIEF FINANCIAL OFFICER 18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 Frank Waung Chief Financial Officer cph10kex322123109.htm 9 EX-32.2]

By | 2016-02-07T23:43:37+00:00 March 4th, 2010|Categories: Chinese Stocks, CPHI, SEC Original|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] 10-K: Form 10-K (Mark one) x For the fiscal

[Form 10-K (Mark one) x For the fiscal year ended: December 31, 2009 o For the transition period from ______________ to _____________ China Pharmas, Delaware 73-1564807 (State or other jurisdiction (I.R.S. Employer I.D. No.)orporation or organization) 2nd Floor, No. 17, Jinpan Road, Haikou, Hainan Province, China 570216 0086-898-66811730 (China)] [Anhui Fuyang Xinte Pharmaceuticalmpany , Sesntract Name of Product Quality standard andecification Unit Unit price Quantity Amount(RMB) Tiopronin 1200.00 1000 1200000 Hepatocyte growthpromoting factor 9000.00 40 3600000 Micro-fiber products 33.00 8000 264000 Medicinal Starch 4.6 5000 23000 Pre-gel starch 8.5 4000 34000 Total amount Five million one hundred and twenty one thousand only] [Raw Material Purchase /lesntractte signed : 2009-03-25 Place: Haikou Accordingly to friendly negotiation, both Partiesree to the term andndition stated following, 1 Name,ecification, quantity and total amount of product Name of Product Quality standard andecification Unit Unit price Quantity Amount(RMB) Brain tissue initial liquid] [Sale sntract of Helpson Medical & Biotechnology C ontract No. Signed at: Arrival port: C ustom No.: B usiness No.: According to the related stipulation of "People's Republic of China Law ofntract", afternsulting unanimously, both sides sign thisntract: NO. Name ofmmodity ,Specifications Unit Quantity] [Sale sntract of Helpson Medical & Biotechnology C ontract No. Signed at: Arrival port: C ustom No. : B usiness No. : According to the related stipulation of "People's Republic of China Law ofntract", afternsulting unanimously, both sides sign thisntract: NO. Name ofmmodity,ecifications] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER OF THERBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 2)Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not] [CERTIFICATION OF CHIEF FINANC IAL OFFICER OF THERBANES-OXLEY ACT OF 2002 I, Frank Waung, certify that: Frank Waung Chief Financial Officer cph10kex312123109.htm 7 EX-31.2] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER 18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 Zhilin Li Chief Executive Officer cph10kex321123109.htm 8 EX-32.1] [CERTIFICATION OF CHIEF FINANCIAL OFFICER 18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 Frank Waung Chief Financial Officer cph10kex322123109.htm 9 EX-32.2]

By | 2016-02-07T23:44:27+00:00 March 4th, 2010|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: (Original Filing)

[Skystar to Present at Upcoming Investor Conferences XI'AN, CHINA — March 2, 2010 — Skystar Bio-Pharmaceutical Company · Rodman & Renshaw Annual China Investment Conference at The Regent Hotel in Beijing, China on March 8, 2010 at 2:25pm Beijing time (1:25am Eastern time); · nd Roth 22 http://www.ir-site.com/skystar/events.asp An audio and slide webcast of each presentation will be available under]

By | 2016-03-01T06:34:42+00:00 March 2nd, 2010|Categories: Chinese Stocks, SEC Original, SKBI|Tags: , , , , , |0 Comments
Skip to toolbar